HFSA expert consensus statement on the medical management of patients on durable mechanical circulatory support
B Trachtenberg, J Cowger, DL Jennings… - Journal of cardiac …, 2023 - Elsevier
The medical management of patients supported with durable continuous flow left ventricular
assist device (LVAD) support encompasses pharmacological therapies administered in the …
assist device (LVAD) support encompasses pharmacological therapies administered in the …
Biomarkers in patients with left ventricular assist device: An insight on current evidence
C Sciaccaluga, N Ghionzoli, GE Mandoli, F D'Ascenzi… - Biomolecules, 2022 - mdpi.com
Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for
patients with end-stage heart failure during the last decades. However, their use induces …
patients with end-stage heart failure during the last decades. However, their use induces …
[HTML][HTML] A Systematic Review and Meta-Analysis of an Angiotensin Receptor–Neprilysin Inhibitor in Patients Using a Durable Left Ventricular Assist Device
Introduction: Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor (ARNI) drug
used to treat patients with heart failure and has shown improvement in outcomes. Different …
used to treat patients with heart failure and has shown improvement in outcomes. Different …
Sacubitril/valsartan off-label uses for Heart failure
Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug
Administration has indicated to reduce the risk of cardiovascular hospitalization and death in …
Administration has indicated to reduce the risk of cardiovascular hospitalization and death in …
New Advances in Medical Management of Left Ventricular Assist Devices Recipients
L Racharla, K Sidhu, H Vidula - Current Treatment Options in …, 2024 - Springer
Abstract Purpose of Review The purpose of this review is to discuss medical management of
patients with left ventricular assist devices (LVADs) and to summarize recent advancements …
patients with left ventricular assist devices (LVADs) and to summarize recent advancements …
[PDF][PDF] What Did We Learn about VADs in 2021?
M Guglin - The VAD Journal, 2022 - digitalcommons.library.tmc.edu
Our previous reports were well received by the readers. The full text of the reviews for 2014,
2015, 2016, 2017, 2018, 2019, and 20201-7 were downloaded 821, 861, 701, 869, 951 …
2015, 2016, 2017, 2018, 2019, and 20201-7 were downloaded 821, 861, 701, 869, 951 …
[PDF][PDF] Sacubitril-Valsartan in LVAD patients: Potentials for the Future
S Arshad, T Haq, D Stephens… - Cardiology and …, 2022 - researchgate.net
Abstract Beneficial effects of Angiotensin Receptor Neprilysin Inhibitors (ARNIs) in heart
failure patients are increasingly being recognized. Current literature on ARNIs among LVAD …
failure patients are increasingly being recognized. Current literature on ARNIs among LVAD …